On Monday, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
In a recent article published in Molecules, researchers discuss using oncolytic viruses (OVs) in combination with nanomaterials as a novel approach to cancer treatment. Their combined use has the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results